<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569178</url>
  </required_header>
  <id_info>
    <org_study_id>BAMI-01</org_study_id>
    <nct_id>NCT01569178</nct_id>
  </id_info>
  <brief_title>BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction</brief_title>
  <acronym>BAMI</acronym>
  <official_title>The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multinational, multicentre, randomised open-label, controlled, parallel-group phase&#xD;
      III study. Its aim is to demonstrate that a single intracoronary infusion of autologous bone&#xD;
      marrow-derived mononuclear cells is safe and reduces all-cause mortality in patients with&#xD;
      reduced left ventricular ejection fraction(&lt;/=45%) after successful reperfusion for acute&#xD;
      myocardial infarction when compared to a control group of patients undergoing best medical&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The advanced therapy treatment product used in this trial is open label, hence no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to all-cause death</measure>
    <time_frame>for an average of 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to cardiac death</measure>
    <time_frame>for an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from randomization to cardiovascular rehospitalisation</measure>
    <time_frame>for an average of 3 years</time_frame>
    <description>time from randomization to cardiovascular rehospitalisation for recurrent MI, coronary revascularisation procedures, heart failure, Implantation of ICD.CRT device, stroke, syncope or Arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of adverse events</measure>
    <time_frame>for an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding by BARC definition</measure>
    <time_frame>for an average of 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Death</condition>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>optimal standard care post myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary Reinfusion of Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow aspiration and intracoronary reinfusion</intervention_name>
    <description>Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique</description>
    <arm_group_label>Intracoronary Reinfusion of Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed and dated informed consent form&#xD;
&#xD;
          -  men and women of any ethnic origin aged≥18years&#xD;
&#xD;
          -  patients with acute ST-elevation myocardial infarction as defined by the universal&#xD;
             definition of AMI (including new LBBB)&#xD;
&#xD;
          -  Patients with acute ST-elevation myocardial infarction as defined by the universal&#xD;
             definition of AMI.&#xD;
&#xD;
          -  Successful acute reperfusion therapy (residual stenosis visually &lt;50% and TIMI flow&#xD;
             ≥2) within 24 hours of symptom onset or thrombolysis within 12 hours of symptom onset&#xD;
             followed by successful percutaneous coronary intervention (PCI) within 24 hours after&#xD;
             thrombolysis&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤ 45% with significant regional wall motion&#xD;
             abnormality assessed by quantitative echocardiography (central, independent core lab&#xD;
             analysis) 2 to 6 days after reperfusion therapy&#xD;
&#xD;
          -  Open coronary artery suitable for cell infusion supplying the target area of abnormal&#xD;
             wall motion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior randomisation unless non&#xD;
             interventional trials or trials where patients are randomised to only standard care&#xD;
             and this has been discussed and agreed with the CI/sponsor prior to consenting&#xD;
&#xD;
          -  Previously received stem/progenitor cell therapy&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study or to follow the protocol&#xD;
&#xD;
          -  Necessity to revascularise additional vessels, outside the target coronary artery at&#xD;
             the time of progenitor cell infusion (additional revascularisations after primary PCI&#xD;
             and before BM-MNC cell infusion are allowed), unless clinically indicated and&#xD;
             according to latest guidelines. This decision should be made at the time of the index&#xD;
             procedure and explicitly stated at that time.&#xD;
&#xD;
          -  Cardiogenic shock requiring mechanical support&#xD;
&#xD;
          -  Platelet count &lt;100.000/µl, or hemoglobin &lt;8.5 g/dl&#xD;
&#xD;
          -  Impaired renal function, i.e. creatinine &gt;2.5 mg/dl&#xD;
&#xD;
          -  Fever or diarrhoea not responsive to treatment within 4 weeks prior screening&#xD;
&#xD;
          -  Cliinically significant bleeding disorder within 3 months prior screening&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt;180 mmHg and diastolic &gt;120 mmHg)&#xD;
&#xD;
          -  Life expectancy of less than two years from any non-cardiac cause or uncontrolled&#xD;
             neoplastic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Mathur, MD, FRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Research Centre VZW</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice BRNO</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Region Hovedstaden</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniLinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitatsklinikum Dusseldorf, Klinik fur Kardiologie, Pneumologie und Angiologie</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt GmbH</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universitaet Frankfurt AM MAIN</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Greifswald Klinik Und Poliklinik Innere Med</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSh Campus Lubeck, Med. Klinik II</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hetzelstift Neustadt</name>
      <address>
        <city>Neustadt</city>
        <zip>67434</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Zentralklinikum Suhl GmbH</name>
      <address>
        <city>Suhl</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm, Clinic of Internal Medicine II</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica Del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>E03-511</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servico Madrileno De Salud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario De Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospiatl Universitatio Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary, University of London (QMUL)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital, Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Norway</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary University of London</investigator_affiliation>
    <investigator_full_name>Anthony Mathur</investigator_full_name>
    <investigator_title>Clinical Director</investigator_title>
  </responsible_party>
  <keyword>stem cells</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>heart failure</keyword>
  <keyword>heart attack</keyword>
  <keyword>bone marrow</keyword>
  <keyword>intracoronary reinfusion</keyword>
  <keyword>bone marrow derived mononuclear cells</keyword>
  <keyword>Left ventricular function improvement</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

